Description:Alzheimer’s Disease (AD) is a fatal neurodegenerative disorder characterized by progressive memory loss, loss of cognitive capacity, mood swings, communication and rationality impairment and eventual loss of independent living. There is still no cure for this disease, but some medicine can delay the progression of symptoms and improve patients’ life quality by acting in the reduction of symptom severity. Acetylcholinesterase inhibitors (AChI) are the main class of drug employed for this. In this context, this research has a goal of evaluating the metabolomic and lipidomic profile of sanguine plasma of patients diagnosed with AD before and after the use of AChI to elucidate metabolic alterations that can assist the diagnosis and contribute to the literature.